Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma.

Li, Yuan Fang; Wang, Yun; Zhou, Jie; Wei, Yi Cheng; Lin, Jun; Yin, Yi Xin; Chen, Guo Ming; Zhang, Fei Yang; Chen, Shi; Zhou, Zhi Wei; Chen, Ying Bo; Cong Nie, Run

Li, Yuan Fang; Wang, Yun; Zhou, Jie; Wei, Yi Cheng; Lin, Jun; Yin, Yi Xin; Chen, Guo Ming; Zhang, Fei Yang; Chen, Shi; Zhou, Zhi Wei; Chen, Ying Bo; Cong Nie, Run.

Afiliación

Li YF; Department of Gastric Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wang Y; State Key Laboratory of Oncology in South China, Guangzhou, China.
Zhou J; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Wei YC; These authors contributed equally to this study.
Lin J; State Key Laboratory of Oncology in South China, Guangzhou, China.
Yin YX; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chen GM; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhang FY; These authors contributed equally to this study.
Chen S; State Key Laboratory of Oncology in South China, Guangzhou, China.
Zhou ZW; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chen YB; Sun Yat-sen University Cancer Center, Guangzhou, China.
Cong Nie R; These authors contributed equally to this study.

World J Oncol ; 13(3): 126-135, 2022 Jun.

Article en En | MEDLINE | ID: mdl-35837321

Palabras clave

Gastro-esophageal carcinoma; Immune checkpoint inhibitor; Overall survival; PD-1; PD-L1; Surrogate endpoint

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: World J Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google